Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Corporate Action: A 1-for-10 reverse stock split became effective on March 13, 2026. All share and per-share data in this filing are retroactively adjusted to reflect this split. The company regained compliance with Nasdaq minimum bid price requirements following the split.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $20,755 | $21,774 |
| Gross Profit | $12,244 | $12,184 |
| Gross Margin | 59.0% | 56.0% |
| Operating Loss | $(1,174) | $(49,668) |
| Net Loss | $(3,424) | $(50,340) |
| Loss Per Share (Basic & Diluted) | $(0.77) | $(11.42) |
| Cash and Cash Equivalents | $7,098 | $5,546 |
| Long-Term Debt (Net) | $36,211 | $35,870 |
| Operating Cash Flow | $(662) | $2,986 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 4.7% to $20.8 million, driven by lower sales to academic research institutions in the Americas and distributors in Asia Pacific.
- Margin Expansion: Gross margin improved to 59.0% from 56.0% due to favorable product mix and prior-year cost reductions.
- Significant Loss Reduction: Net loss narrowed significantly to $3.4 million from $50.3 million. The prior year included a non-cash goodwill impairment charge of $48.0 million; no such charge was recorded in Q1 2026.
- Increased Interest Expense: Interest expense rose 85.2% to $1.7 million due to higher interest rates and amortization of deferred financing costs associated with the new 2025 Loan Agreement.
- Cash Flow Shift: Operating cash flow turned negative ($0.7 million used) compared to positive ($3.0 million provided) in the prior year, primarily due to a $1.5 million cash outflow for inventory buildup.
Outlook, Risks, and Management Commentary
- Project Viking Restructuring: In January 2026, the company initiated "Project Viking" to consolidate manufacturing operations (closing Holliston, MA; shifting to Minneapolis, MN, and international hubs). The company expects $3.4 million to $4.4 million in pre-tax restructuring charges, with annual cost savings of $4 million beginning in 2028.
- Debt Refinancing: The company completed a refinancing in December 2025 (2025 Loan Agreement) with a total principal of $40 million. The agreement includes a minimum liquidity covenant of $3.0 million and a minimum adjusted EBITDA covenant of $6.0 million (trailing 12-month). The company was in compliance as of March 31, 2026.
- Going Concern: Management concluded that substantial doubt regarding the company's ability to continue as a going concern has been alleviated following the debt refinancing.
- Risk Factors:
- Delisting Risk: While the company regained Nasdaq compliance via the reverse stock split, failure to maintain listing standards in the future could lead to delisting.
- Legal Proceedings: A potential breach of contract claim was received in January 2026. Management estimates a potential loss range of $0.1 million to $0.8 million.
- ERTC Liability: $6.8 million in Employee Retention Tax Credit (ERTC) funds are recorded as a liability pending audit resolution (statute of limitations expires May 2029).
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the minimum liquidity ($3M) and adjusted EBITDA ($6M) covenants under the 2025 Loan Agreement.
- Restructuring Execution: Monitor the progress of "Project Viking" and the actual realization of projected cost savings versus the incurred charges.
- Inventory Levels: Assess the impact of the $1.5 million inventory buildup on future working capital and cash flow.
- ERTC Audit Status: Track the status of the $6.8 million ERTC liability to determine if funds will be retained or required to be returned.
- Stock Price Stability: Confirm the company maintains the minimum bid price requirement on Nasdaq following the 1-for-10 reverse split.